Natasha Albaneze

Dec 4, 2024 | onlinelibrary.wiley.com | Natasha Albaneze |Cary C. Cotton |Chelsea Anderson |David A. Katzka

Data Availability Statement The data that support the findings of this study are available from Merative MarketScan. Restrictions apply to the availability of these data, which were used under licence for this study.

Nov 21, 2024 | pharmacypracticenews.com | Natasha Albaneze

Originally published by our sister publication Infectious Disease Special EditionThe benefits of vaccination with recombinant zoster vaccine (RZV; Shingrix, GSK) outweigh safety concerns in immunocompromised populations, according to a systematic review of studies involving multiple patient groups. Patients who are immunocompromised, either due to their medical condition or immunosuppressive treatments, are at an elevated risk for herpes zoster.